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The viral capping enzyme nsP1: a 
novel target for the inhibition of 
chikungunya virus infection
L. Delang1, C. Li2,3, A. Tas4, G. Quérat5, I. C. Albulescu4, T. De Burghgraeve1, 
N. A. Segura Guerrero1, A. Gigante6, G. Piorkowski5, E. Decroly2,3, D. Jochmans1, B. Canard2,3, 
E. J. Snijder4, M. J. Pérez-Pérez6, M. J. van Hemert4, B. Coutard2,3, P. Leyssen1,* & J. Neyts1,*
The chikungunya virus (CHIKV) has become a substantial global health threat due to its massive re-
emergence, the considerable disease burden and the lack of vaccines or therapeutics. We discovered a 
novel class of small molecules ([1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones) with potent in vitro activity 
against CHIKV isolates from different geographical regions. Drug-resistant variants were selected 
and these carried a P34S substitution in non-structural protein 1 (nsP1), the main enzyme involved in 
alphavirus RNA capping. Biochemical assays using nsP1 of the related Venezuelan equine encephalitis 
virus revealed that the compounds specifically inhibit the guanylylation of nsP1. This is, to the best of 
our knowledge, the first report demonstrating that the alphavirus capping machinery is an excellent 
antiviral drug target. Considering the lack of options to treat CHIKV infections, this series of compounds 
with their unique (alphavirus-specific) target offers promise for the development of therapy for CHIKV 
infections.
Chikungunya virus (CHIKV) is an arthropod-borne virus that is primarily transmitted by Aedes aegypti and 
Aedes albopictus mosquitoes. Before 2004 only sporadic and relatively limited outbreaks were reported, but 
later large-scale outbreaks have occurred in many tropical regions in Africa and Asia1. Concomitantly, multiple 
imported cases among travelers returning from endemic areas have been reported in several European countries, 
the USA, Canada and Australia. Because of the spread of in particular the Aedes albopictus mosquito to more 
temperate regions such as Southern Europe, Northern Asia and the Americas, it was anticipated that CHIKV 
has the potential to become endemic in new regions2,3. In December 2013, the first locally transmitted infections 
were reported in the Americas on the Caribbean island of Saint Martin. From there, the virus has been spreading 
further to neighboring countries in the Caribbean and South as well as Central America4. Over 1.6 million cases 
have been reported till October 2015 in the Americas by the WHO/PAHO. Severe and fatal acute CHIKV infec-
tions have also been described during this continuing epidemic5,6.
Chikungunya fever is mostly characterized by a very painful arthralgia that usually resolves within several 
days7. Although CHIKV infections are rarely fatal, up to 60% of the patients develop a chronic disease that is 
characterized by persistent and often disabling polyarthritis, which can severely incapacitate the patient for weeks 
up to several years after the acute infection8. Due to the severe symptoms and its re-emergence on a massive 
scale, CHIKV has become a substantial public health problem. There is no approved vaccine or antiviral drug 
available for the prevention or treatment of this infection. Patients are currently given analgesics, antipyretics and 
anti-inflammatory agents to alleviate their symptoms. Chloroquine, a drug that is commonly used for the treat-
ment of malaria, was demonstrated to have a dose- and time-dependent inhibitory effect on CHIKV replication 
in vitro9, but clinical studies failed to prove its efficacy in infected patients10,11. We demonstrated that Favipiravir 
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(T-705, approved in Japan for the treatment of influenza infections) exerts anti-CHIKV activity in vitro and in 
a mouse model12. Several other molecules with in vitro anti-CHIKV activity have been reported13, but to our 
knowledge, none of these molecules have progressed towards further development.
We recently identified - in a large scale cell-based antiviral screening campaign - 3-(3′-acetylphenyl)-5-met
hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (MADTP-314) as a selective inhibitor of CHIKV replication. 
Following initial hit-optimization more potent analogs were obtained14. We here report on the unique molecular 
mechanism by which these compounds inhibit CHIKV replication, through targeting the alphavirus capping 
machinery.
Results
Antiviral activity of the MADTP-series against chikungunya virus and other alphaviruses. 
Based on the initial hit MADTP-314 (Fig. 1), several series of MADTP compounds were synthesized and their 
efficacy was tested against the laboratory-adapted CHIKV strain 89914. The most potent and selective analog 
in this series identified so far, 5-ethyl-3-(3-isopropoxyphenyl)-3H-[1,2,3]triazolo[4,5-d]-pyrimidin-7(6H)-one 
(MADTP-372, Fig. 1), inhibited the induction of the cytopathic effect (CPE) by CHIKV with an EC50 value of 
2.6 μM (CC50 > 400 μM) (Table 1)14. Combining the ethyl substituent at position 5 of the heterocyclic base in 
MADTP-372 and the 3′-acetyl group at the aryl moiety present in the initial hit (MADTP-314) led to the synthe-
sis of MADTP-393 (the synthesis of this molecule will be published elsewhere). This MADTP analog had a better 
anti-CHIKV profile than MADTP-314, but was not as potent as MADTP-372 (Table 1). MADTP-346 is a close 
structural analog that was devoid of anti-CHIKV activity.
The antiviral activity of selected MADTP analogues was next validated by quantifying the release of viral RNA 
in the supernatant by qRT-PCR. The MADTP-series proved active against clinical isolates of CHIKV, with the 
Congo 95 strain (clinical isolate of 2011) being the most susceptible [as shown for MADTP-314, -372 and -393 
(Table 1)]. No or modest antiviral activity was observed against other alphaviruses such as the Sindbis virus, the 
Semliki forest virus, the O’Nyong Nyong virus, the Barmah forest virus, the Mayaro virus and the Ross River virus 
(data not shown). Only MADTP-372 significantly inhibited the replication of Venezuelan equine encephalitis 
virus (VEEV) in cell culture (Table 1).
The mechanism of action of MADTP-314. MADTP-314 was selected (at the time of the ongoing 
hit-optimization process the most potent/selective inhibitor in the series) as the prototype of this class of 
molecules to study the particular characteristics and the mechanism of action of its anti-CHIKV activity. 
Time-of-addition studies revealed that MADTP-314 had an inhibition profile that was comparable to that of 
a polymerase-targeting compound (T-70512), i.e. the compound remained active when addition to the infected 
cultures was delayed by several hours (up to 6 h) post infection (1.3 log10 and 1.0 log10 reduction in CHIKV RNA 
for MADTP-314 and T-705, respectively, when added 6h post infection and assessed at 24 h post infection). In 
contrast, chloroquine, a CHIKV entry inhibitor included as a reference compound, entirely lost its protective 
activity when added at time points later than 1 h p.i., whereas a 2 log10 reduction of CHIKV RNA was obtained 
when the compound was added 2 h before infection. To study whether MADTP-314 can block CHIKV cell entry, 
CHIKV pseudoparticles (CHIKVpp) were produced as described before15. These pseudoparticles are lentiviral 
vectors carrying CHIKV glycoproteins and are thus ideally suited to study CHIKV entry independently from 
post entry steps in the viral life cycle. In line with the time-of-addition experiments, MADTP-314 and analogs 
Figure 1. Chemical structures of MADTP-314, MADTP-346, MADTP-372 and MADTP-393. 
Species Virus (strain) MADTP-314 MADTP-372 MADTP-393
CHIKV
899 (lab) 26 ± 11a 2.6 ± 1.0a 18 ± 6.4a
Venturini (Italy 2008) 26 ± 2b 1.4 ± 0.01b 8.2 ± 2.2b
Congo 95 (2011) 6.4 ± 0.1b 0.75 ± 0.4b 1.4 ± 0.3b
VEEV TC83 >40b 6.8b 35 ± 10b
Table 1.  In vitro antiviral activity of analogs in the MADTP series against CHIKV and VEEV. aCPE 
reduction, bviral RNA reduction. VEEV: Venezuelan equine encephalitis virus. Data shown are average 
values ± SD of at least two independent experiments. CC50 values for MADTP-314, MADTP-372 and MADTP-
393 on Vero cells are >743 μM, >668 μM and 57 ± 28 μM, respectively.
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were not able to block the entry of CHIKV pseudoparticles (CHIKVpp) into the host cell (Fig. 2a). In contrast, 
CHIKV entry inhibitors such as arbidol and chloroquine inhibited CHIKVpp entry in a dose-dependent man-
ner (Fig. 2a)9,16. To assess whether MADTP-314 (directly) affects translation of incoming capped CHIKV RNA 
genomes, cells were transfected with a replication-deficient CHIKV RNA (carrying an active site mutation in the 
RNA polymerase domain of nsP4) encoding an nsP3-luciferase fusion protein, which allowed measuring trans-
lation independent of RNA replication. Luciferase activity in cells treated with 250 μM MADTP-314 was compa-
rable to that in untreated control cells, suggesting that the compound did not directly inhibit translation of the 
incoming, capped genomic RNA (Fig. 2b). Next we assessed whether MADTP-314 had a direct inhibitory effect 
on CHIKV RNA synthesis as quantified by measuring 3H-uridine incorporation into newly synthesized CHIKV 
RNA. In CHIKV-infected cells, MADTP-314 (50–250 μM) did not inhibit CHIKV RNA synthesis (Fig. 2c). This 
was confirmed in an in vitro assay with isolated replication/transcription complexes (RTCs)17, which demon-
strated that 250 μM of MADTP-314 did not inhibit the incorporation of 32P-CTP into CHIKV RNA (Fig. 2d). 
Taken together these results demonstrate that MADTP-314 inhibits CHIKV replication at a post-entry step, other 
than translation or viral RNA synthesis.
Selection and characterization of MADTP-314-resistant CHIKV variants. To identify the viral protein 
that is targeted by the MADTP compounds, CHIKV variants with resistance to MADTP-314 were selected. To 
this end a 5-step resistance selection protocol was used as described before12. Three MADTP-314-resistant virus 
isolates were independently obtained from a heterogeneous (quasi-species) wild-type population of CHIKV 
(strain 899). All three variants proved ~11-fold less sensitive to the antiviral effect of the compound (Table 2). The 
selected resistant variants were cross-resistant to the antiviral effect of other MADTP analogs. No cross-resistance 
to chloroquine or T-705 was observed (Table 2), suggesting a different mechanism of action for the MADTP 
compounds.
A total of five mutations were identified in the 3 variants by means of population sequencing, including a 
mutation in the nsP1 gene (Supplemental Table 1). This P34S substitution in nsP1 was the only amino acid change 
that all three of the MADTP-314-resistant isolates had in common. Interestingly, P34 is located near a conserved 
histidine at position 37 in a region of nsP1 known to contain several key residues for the mRNA capping func-
tions (Supplemental Figure 1A,B)18.
Figure 2. Mechanism of action of the MADTP series. (a) Huh 7.5.1 cells treated with different MADTP 
compounds were infected with CHIKV pseudoparticles. Arbidol and chloroquine were used as positive 
controls. The entry of CHIKVpp was determined by measuring the luciferase activity. The average values ± SD 
of three independent experiments are shown. (b) Cells were transfected with a replication-deficient CHIKV 
RNA encoding an nsP3-Rluc fusion protein, in the presence or absence of MADTP-314. Subsequently, luciferase 
activity was determined at 2.5, 5 and 7.5 h post-transfection. (c) CHIKV-infected Vero E6 cells (MOI 5), treated 
with 50, 100 and 250 μM MADTP-314, were metabolically labeled with 3H-uridine from 6–7 h p.i. Total RNA 
was isolated and separated by denaturing agarose gel electrophoresis, followed by fluorographic detection of 
3H-labeled RNA. (d) In vitro RNA synthesizing activity of isolated CHIKV RTCs in the presence or absence of 
250 μM MADTP-314, quantified by measuring the incorporation of 32P-CTP. RNA II is a 7.5 kb CHIKV RNA 
that corresponds to the 5′-proximal 7.5 kb of the CHIKV genome up to the subgenomic promoter region17.
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Involvement of the P34S substitution in the MADTP-resistant phenotype. The mutation that 
causes the P34S substitution in nsP1 was introduced into infectious clone CHIKV LS319 by reverse genetics. 
Serial passaging on Vero E6 cells in the absence of MADTP and sequencing of the virus revealed that the muta-
tion was stable for at least 5 passages and did not markedly affect viral fitness. Indeed plaque morphologies of 
CHIKV-LS3-nsP1-P34S and WT CHIKV-LS3 were comparable (Fig. 3a) and the P34S mutant replicated only 
slightly slower than WT in growth curve experiments (Fig. 3b). Western blot analysis of CHIKV‐infected Vero 
E6 cells at various time points p.i. indicated that the accumulation of nsP1 in cells infected with the P34S mutant 
virus was somewhat reduced compared to WT (Fig. 3c). The P34S mutation thus seems to only modestly affect 
the growth characteristics of the virus.
Next, using a CPE-based antiviral assay, the sensitivity to MADTP-314, MADTP-372, and MADTP-393 was 
determined for CHIKV-LS3-nsP1-P34S and the parental WT CHIKV-LS3 (Table 2). In contrast to the WT virus, 
the reverse-engineered mutant nsP1-P34S virus proved to be highly resistant to the antiviral effect of the three 
different MADTP compounds [it should be noted that CHIKV strain LS3 was 1.5-fold less sensitive to MADTP-
314 than CHIKV 899]. By analyzing CHIKV protein expression in infected cells, the nsP1-P43S mutant virus was 
also shown to be highly resistant to MADTP-314, as nsP1 and E2E3 proteins were easily detected in cells treated 
with MADTP-314 concentrations above 63 μM, whereas such treatment resulted in hardly detectable expression 
of CHIKV proteins in cells infected with the WT virus (Fig. 4). In conclusion, these results clearly linked the 
nsP1-P34S mutation to phenotypic resistance to MADTP compounds.
Effect of MADTP molecules on the alphavirus capping machinery. The alphavirus nsP1 protein 
possesses both methyltransferase (MTase) and nsP1 guanylyltransferase (GT) activities. The protein catalyzes 
the transfer of the methyl group from S-adenosylmethionine (AdoMet) to the N7 position of a GTP molecule, 
which is followed by the formation of an m7GMP-nsP1 adduct. The subsequent transfer of m7GMP onto the 5′ 
end of the viral RNA has been recently demonstrated in vitro for VEEV nsP118. To explore the potential effect 
of the MADTP-series on the in vitro enzymatic activity of nsP1, we extensively attempted to purify recombinant 
CHIKV nsP1 from E. coli, but unfortunately failed to obtain enzymatically active protein. Since in vitro assays 
were available for purified VEEV nsP1, we assessed the anti-VEEV activity of the MADTP compounds and found 
that MADTP-372 caused a significant inhibition of VEEV replication in cell culture (Table 1, EC50 of 6.8 μM). We 
therefore decided to assess the effect of this compound on the enzymatic activities of VEEV nsP1 using the avail-
able biochemical assays. The results of the expression, purification and GTase activity of both CHIKV and VEEV 
nsP1 are shown in Supplemental Figure 2.
The in vitro guanylyltransferase activity of VEEV nsP1 was quantified by measuring the formation of the 
m7GMP-nsP1 complex by Western blotting, using m7GTP as a substrate and an anti-methyl3/7Gp antibody 
EC50 (μM)
Resistance selection Reverse genetics
WT 899 MADTP-314res variant 3 WT LS3 LS3-P34S
MADTP-314 26 ± 11 283 ± 45 40 ± 5.0 >500
MADTP-372 2.6 ± 1.0 255 ± 16 4.9 ± 0.6 >50
MADTP-393 18 ± 6.4 193 ± 14 15 ± 0.8 >50
Chloroquine 18 ± 11 20 ± 4.7 n.d. n.d.
T-705 20 ± 2.7 34 ± 5.7 n.d. n.d.
Table 2.  In vitro anti-CHIKV activity of MADTP molecules against WT and resistant CHIKV variants. 
n.d.: not determined. Data shown are average values ± SD of at least two independent experiments.
Figure 3. Characterization of the CHIKV LS3-nsP1-P34S mutant. (a) Plaque morphology of CHIKV LS3 
and mutant CHIKV LS3-nsP1-P34S at 3 days post infection. The plaque assay was performed on Vero E6 cells 
as described in ref. 19. (b) Growth curve of CHIKV LS3 (black) and mutant CHIKV LS3-nsP1-P34S (grey) 
on Vero E6 cells (MOI 0.05). Virus titers were determined by plaque assay on Vero E6 cells at 3 days p.i. Data 
shown are average values of two independent experiments. (c) The expression of nsP1 in Vero E6 cells infected 
with WT CHIKV LS3 or the nsP1-P34S mutant virus at various time points post infection (MOI 0.05) analyzed 
by Western blot.
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for detection. MADTP-372, and to a lesser extent MADTP-314, inhibited the GT activity of VEEV nsP1 in a 
concentration-dependent manner (Fig. 5a). In contrast, MADTP-346, an analog devoid of antiviral activity 
in cell culture, did not inhibit the GT activity of VEEV nsP1. To further characterize the mode of action of 
MADTP compounds, the MTase activity of VEEV nsP1 was quantified by a filter-based assay using 3H-AdoMet. 
MADTP-314, MADTP-346 and MADTP-372 did not or only modestly inhibit the MTase activity of VEEV nsP1 
(IC50 > 1000 μM) (Fig. 5b).
Resistance of VEEV nsP1-D34S to MADTP-372. To assess the role of the amino acid at position 34 in 
the molecular mechanism of the antiviral resistance against the MADTP series, D34 (corresponding to CHIKV 
P34) of VEEV nsP1 was mutated to a serine. The GT activity of the recombinant VEEV nsP1 was barely affected 
by the D34S mutation (Fig. 5c). Thus, the inhibitory effect of MADTP-372 on the GT reaction could be assessed 
for both the WT and the mutated protein. The D34S mutation alleviated the inhibitory effect of the compound 
on the GT reaction with IC50 values increasing from 10 ± 0.3 μM for WT to ~1000 μM for the mutant protein 
(Fig. 5d). These biochemical assays on WT and mutant D34S VEEV nsP1 thus confirmed that the MADTPs target 
the enzymatic activity of nsP1.
Discussion
Many RNA viruses have adopted a strategy to modify the 5′ end of their genome by the covalent attachment of 
a peptide or the introduction of a cap moiety to ensure efficient translation, to protect their RNA from degrada-
tion by cellular 5′-3′ exonucleases, and to avoid detection as foreign RNA (which can trigger an innate immune 
response)20. Through a non-conventional cytoplasmic capping mechanism, alphaviruses synthesize the minimal 
RNA cap chemical structure, named cap-0 (m7GpppNp-RNA, in which N is the first nucleotide of the viral RNA, 
p represents a phosphate and m represents a methyl group)20. Several reactions are required for the synthesis of 
the alphavirus cap structure. The N7 position of GTP is first methylated by the methyltransferase activity of nsP1 
using S-adenosylmethionine as a methyl-donor. Next a covalent m7GMP-nsP1 complex is formed from which the 
m7GMP is transferred to the viral RNA. The amino acid binding covalently to m7GMP has never been character-
ized directly, but histidine 37 has been proposed as the best candidate18,21,22. Before guanylyltransfer to the viral 
RNA can occur, the 5′ gamma-phosphate of the nascent viral RNA chain is removed by an RNA 5′-triphosphatase 
residing in the nsP2 protein23,24.
Since RNA capping is an essential step in the replication cycle of alphaviruses (and many other viruses) and 
since it differs from the host cell’s mechanism by its localization and reaction sequence, this process may be a 
potential target for antiviral drug development. For instance, the cap-snatching mechanism by which ortho-
myxoviruses acquire their cap has been shown to be a good target for inhibitors of influenza virus replication25. 
Only a few selective inhibitors of viral RNA cap formation have been reported till now26, and to the best of our 
knowledge, none of them affect alphavirus capping. Inhibitors of viral capping that were previously reported tar-
get the MTases of flaviviruses and coronaviruses26. However, these MTase inhibitors mostly encompass GTP and 
Figure 4. Sensitivity of WT and nsP1-P34S mutant virus to MADTP-314. Effect of various concentrations 
of MADTP-314 on the expression of nsP1 and the structural protein E2 of WT CHIKV LS3 and the P34S-LS3 
mutant CHIKV in infected Vero E6 cells (MOI 0.1) that were analyzed by Western blotting at 28 h p.i. 
Percentages of untreated control are presented below the blots. The anti-E2 antibody was a gift of Dr. G. 
Pijlman34, the anti-nsP1 antibody was published before in ref. 33.
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S-adenosylmethionine/homocysteine analogs27, which raises concerns about their specificity and potential toxic-
ity (through their effect on host MTases). For alphaviruses, the capping mechanism driven by the multifunctional 
nsP1 protein could be an attractive target for antiviral treatment since it differs from its cellular counterpart. 
However, the fact that no structure of alphavirus nsP1 proteins have been reported has hampered the develop-
ment of capping inhibitors by structure-based drug design28.
We here demonstrate for the first time that small molecule inhibitors of the alphavirus nsP1 RNA capping 
machinery are able to efficiently and completely abolish CHIKV replication in vitro at concentrations that have 
no adverse effect on the host cell. As shown with the prototype compound MADTP-314, these triazolopyrimidi-
nones do not inhibit CHIKV entry, which was corroborated by time-of-drug-addition experiments. Transfection 
of cells with replication-incompetent CHIKV RNA revealed that MADTP-314 did not directly affect the transla-
tion of incoming capped genomes, demonstrating that there is no cap-independent modulation of viral protein 
Figure 5. Effect of MADTP compounds on the methyltransferase and the guanylyltransferase activity 
of VEEV nsP1. (a) Effect of different concentrations of MADTP-372, MADTP-314 and MADTP-346 on 
the in vitro guanylylation of VEEV nsP1. The m7GMP-nsP1 complex was detected by Western blot with an 
anti-methyl3/7Gp antibody. (b) Dose-response curves of MADTP-314 (circles), MADTP-346 (triangles), and 
MADTP-372 (squares) on the methyltransferase activity of VEEV nsP1. The nsP1-MTase product (3H-methyl) 
GIDP was measured by a scintillation counter. The average values ± SD of two independent experiments are 
shown. (c) Relative nsP1 guanylylation activity (% WT) of the D34S-nsP1 mutant in the absence of compounds. 
(d) Relative nsP1 guanylylation activity (% untreated control) of WT and D34S VEEV nsP1 when treated with 
different concentrations of MADTP-372. The average values ± SD of two independent experiments are shown.
www.nature.com/scientificreports/
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synthesis. The compound also had no direct effect on CHIKV RNA synthesis. Compound-resistant virus variants 
were selected that carried the P34S mutation in the nsP1 protein and reverse genetics confirmed that this muta-
tion is responsible for resistance to MADTP-314.
To explore the effect of this class of compounds on the enzymatic functions of the CHIKV nsP1 protein, 
we set out to express and purify this protein. However, despite dedicated efforts, we were not able to obtain 
enzymatically active CHIKV nsP1. Interestingly, MADTP-372, a close structural analog of MADTP-314, also 
inhibited VEEV replication in cell culture. The anti-VEEV effect of MADTP-372 led us to assess the effect of 
this compound on the enzymatic activity of the VEEV nsP1, for which we previously succeeded to obtain enzy-
matically active recombinant protein18. A clear dose-dependent inhibition of the guanylyltransfer (GT) activity 
was observed in a Western blot-based assay. MADTP-314 also showed a modest inhibitory effect on the GTase 
activity, while MADTP-346, an analog devoid of anti-CHIKV activity in cell culture14, proved virtually inactive 
against the GT activity of purified VEEV nsP1. So far we were unable to select MADTP-resistant VEEV variants.
Previous sequence analysis and functional studies have shown that the sequence surrounding amino acid 34 of 
nsP1, which is mutated in MADTP-resistant variants, is a key domain for alphavirus mRNA cap synthesis18. It is 
located at the beginning of the core region that carries both MTase and GT activities28. More precisely, nsP1 H37, 
the amino acid that is the putative acceptor for the guanylylation, is in close proximity to P34. At this stage, in the 
absence of information on the structure of alphavirus nsP1, it would be tempting to propose that MADPTs inhibit 
the GT reaction by hampering either the binding of m7GTP or the catalysis of the guanylylation itself. However, 
other possible scenarios that involve indirect effects cannot be ruled out.
It is intriguing that, despite the well conserved, enzymatically active part of alphavirus nsP1, the reported 
series of compounds does not inhibit closely related alphaviruses like ONNV. It could be that some alphaviruses 
have mechanisms to overcome defects in cap-synthesis activity. It was also shown recently that SINV produces 
non-capped viral genomic RNAs, especially in significant numbers during the early phase of infection29. It is not 
clear whether this is also the case for CHIKV or other alphaviruses. It may thus be that CHIKV does not have this 
mechanism and that it is therefore very sensitive to nsP1 inhibitors. The optimization of this compound series is 
still ongoing and we observed that the second generation of compounds has a modest antiviral activity against 
ONNV (EC50 values between 15–25 μM).
As there are currently no options to treat infections with the re-emerging CHIKV, the MADTP compounds 
with their unique (alphavirus-specific) target provide a promising starting point to develop therapy for CHIKV 
infections (and for which the classical preclinical and clinical studies need to be carried out). In such case that 
the structure of the nsP1 of CHIKV or of another alphavirus would be resolved in the future, this could enable 
structure-based drug design of new classes of capping inhibitors. It remains to be studied (first in animal models) 
whether or not CHIKV inhibitors may have a beneficial effect on chronic infections of the joints with this virus. If 
this were to be the case, this will offer important options for the management of this debilitating condition. Potent 
and safe CHIKV inhibiting drugs may also be used prophylactically, for example in travelers to endemic regions 
or as household prophylaxis.
In conclusion, we here report for the first time on a class of small-molecule inhibitors of CHIKV replication 
that block the guanylyltransferase activity of nsP1, thereby preventing the formation of capped viral mRNA. We 
thus provide proof that the (alpha)viral RNA capping machinery is a druggable target for the development of 
desperately needed, selective and potent antiviral therapy against CHIKV.
Methods
Cells and virus strains. CHIKV Indian Ocean strain 899 (Genbank FJ959103.1) was generously provided 
by Prof. C. Drosten (University of Bonn, Germany)30. The clinical isolates Venturini and Bianchi (Italy 2008) and 
Congo 95 (2011) belong to the collection of viruses at the UMR 190, Marseille, France, as well as O’Nyong Nyong 
virus strain IPD A234, Mayaro virus strain TC625, Barmah Forest virus strain BH2193, VEEV vaccine strain 
TC83. Ross River virus 5281v was received from the National Collection of Pathogenic Viruses (UK). CHIKV 
LS3 (GenBank KC149888) that was used for reverse genetics studies is derived from an infectious cDNA clone 
belonging to the collection of the Leiden University Medical Center, The Netherlands19. Sindbis virus (SINV, 
strain HRsp, GenBank J02363.1) and the Semliki Forest virus (SFV, Vietnam strain, GenBank EU350586.131) 
belong to the collection of viruses at the Rega Institute of Medical Research, Belgium. All viruses were propagated 
in African green monkey kidney cells [Vero cells (ATCC CCL-81)].
Vero A cells were maintained in cell growth medium composed of minimum essential medium (MEM Rega-3) 
supplemented with 10% Foetal Bovine Serum (FBS), 1% l-glutamine, and 1% sodium bicarbonate. Vero E6 cells 
were maintained in Eagle MEM supplemented with non-essential amino acids and 7.5% FBS. Huh 7.5.1 cells were 
maintained in Dulbecco’s modified essential medium (DMEM) supplemented with 10% FBS, 1% HEPES, 1% 
non-essential amino acids and 1% penicillin-streptomycin. The antiviral assays were performed in virus growth 
medium which is the respective cell growth medium supplemented with 2% (instead of 10%) FBS. All cell cultures 
were maintained at 37 °C in an atmosphere of 5% CO2 and 95–99% humidity.
Compounds. The synthesis of MADTP-314, MADTP-346 and MADTP-372 was described previously14. The 
synthesis of MADTP-393 will be reported elsewhere. The structures of the compounds are depicted in Fig. 1. 
Compounds were dissolved in analytical grade dimethyl sulfoxide (DMSO). T-705 (favipiravir) was purchased as 
a custom synthesis product from BOC Sciences. Chloroquine was purchased from Sigma and dissolved in PBS. 
Arbidol was a kind gift of Prof. S. Polyak (University of Washington, Seattle, USA).
Antiviral assays. Vero A cells were seeded in 96-well tissue culture plates at a density of 2.5 × 104 cells/well 
in 100 μl assay medium and were allowed to adhere overnight. Next, a compound dilution series was prepared 
after which the cultures were infected with 0.001 MOI of CHIKV 899 inoculum in 100 μl assay medium. On day 
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5 post-infection (p.i.), the plates were processed using the MTS/PMS method as described by the manufacturer 
(Promega). The 50% effective concentration (EC50) was determined using logarithmic interpolation. Potential 
cytotoxic/cytostatic effects of the compound as well as the longevity of Vero cells were evaluated in uninfected 
cells by means of the MTS/PMS method. The 50% cytotoxic concentration (CC50) was calculated using logarith-
mic interpolation. All assay wells were checked microscopically for minor signs of virus-induced CPE or possible 
alterations to the cell or monolayer morphology caused by the compound.
A variant of this protocol was used for the reverse-engineered CHIKV LS3 virus. Briefly, 1 × 104 Vero E6 cells 
were seeded per well in a 96-well tissue culture plate and infected the next day at an MOI of 0.001. On day 4 p.i., 
the plates were processed using the MTS/PMS method. EC50 and CC50 values were calculated using non-linear 
regression with Graphpad Prism.
For the other CHIKV strains as well as for the additional alphaviruses, another variant of this protocol was 
used. For these viruses, Vero E6 cells were seeded in 2.5% supplemented Foetal Calf Serum (FCS) medium. The 
next day, two-fold serial dilutions of the compounds were added to the cells (25 μl/well). Fifteen minutes later, 
25 μl of a virus mix containing the appropriate amount of viral stock dilution in medium was added to the 96-well 
plates. Cells were cultivated for 2 days and viral RNA was isolated as was described previously12.
CHIKV quantitative reverse transcription-PCR (qRT-PCR). CHIKV clinical isolates from Italy, 
Congo and Saint Martin were quantified by real time RT-PCR to determine viral RNA yield (SuperScript III 
Platinium one-step RT-PCR with Rox from Invitrogen), using CHIK-F2 TGGAATGGCTGGTTAACAAGATAA, 
CHIK-R2 CTCCGCGGACACCTAACG (except Congo strain: CHIK-R3 CTCCGCGGACACCTAWSG) and 
probe FAM-CTACTAAGAGAGTCACTTGGGTAG-MGB. Primers for amplification of other alphaviruses were 
described before12. For absolute quantification, standard curves were generated using 100-fold dilutions of T7 
polymerase-generated RNA of known quantities for each virus. qRT-PCR was performed on a ABI 7900 HT Fast 
Real-Time PCR System, using 20 min at 50 °C and 3 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min 
at 60 °C.
Entry assay using CHIKV pseudoparticles. The protocol for the generation of CHIKV pseudotyped 
viruses was adapted from15. To generate the CHIKV glycoproteins expression vector, an expression cassette for 
E3/E2/E1 containing amino acids 262–1248 of the structural polyprotein was synthesized by RT-PCR on RNA 
isolated from the supernatant of CHIKV 899-infected cells. The expression cassette was subsequently cloned into 
vector pJET1.2 (Fermentas) by blunt-end ligation, after which it was cloned into the mammalian expression plas-
mid pcDNA3.1/Neo+ (Invitrogen) using NotI and XbaI. CHIKV pseudoparticles were produced essentially as 
described previously32 by transfecting HEK293T cells using a calcium phosphate based transfection protocol with 
2 μg of the plasmid encoding the CHIKV envelope proteins, 2 μg of the packaging construct pBS-CMV-GagPol (a 
gift from Prof. Patrick Salmon (Addgene plasmid # 35614)) and 2 μg of a vector encoding luciferase as a marker pro-
tein (pGL3-Luc). Following 48 h of incubation at 37 °C the supernatant was collected and frozen at −20 °C. To eval-
uate the effect of MADTP molecules on CHIKVpp entry, Huh 7.5.1 cells were seeded at a density of 5000 cells/well 
in a white 96-well cell culture plate and allowed to adhere overnight at 37 °C. The next day, serial dilutions of the 
compounds and 100 μl of a 1/8 dilution of the CHIKVpp were added to the cells. As described before15, following 
72 h of incubation at 37 °C, the cells were lysed and the luciferase activity was measured according to the manu-
facturer’s protocol (Luciferase Assay System, Promega).
CHIKV translation assay. Translation of (non-replicating) CHIKV RNA into non-structural proteins was 
quantified basically as described33 except that Vero E6 cells were used (5 × 103 per well) and replication-deficient 
CHIKV RNA (mutation in nsP4 active site) encoding a nsP3-Rluc fusion protein was transfected (100 ng per 
well). At 2.5, 5 and 7.5 h post transfection, cells were lysed in passive lysis buffer (Promega) and luciferase sub-
strate was added according to the manufacturer’s instructions. Luciferase activity was measured in a GloMax 96 
microplate luminometer (Promega).
Metabolic labeling with 3H-uridine, in vitro RTC assay, denaturing agarose electrophoresis and 
in-gel hybridization. Actinomycin D (ActD; Sigma-Aldrich) was added to a final concentration of 5 μg/ml 
to 2.8 × 105 CHIKV infected (MOI 5) or mock-infected Vero E6 cells in 12-well clusters at 5.5 h p.i. At 6 h p.i. viral 
RNA synthesis was labeled by adding 40 μCi of [3H]uridine to the medium. At 7 h p.i. total RNA was isolated and 
separated in denaturing agarose gels as described19. 3H-labeled RNA was visualized by fluorography. To correct 
for variations in loading, the gel was hybridized with a 32P-labeled oligonucleotide probe recognizing 18S riboso-
mal RNA. Detection of positive strand CHIKV RNA by in-gel hybridization with a 32P-labeled probe complemen-
tary to the 3′ end of the genome was done as described19. 3H-labeled RNA was quantified by scintillation counting 
and by fluorography and densitometry of scanned films. Hybridized gels were analyzed using PhosphorImager 
screens and a Typhoon 9410 imager (GE Healthcare), followed by quantification with Quantity One (BioRad). 
The RNA synthesizing activity of isolated CHIKV RTCs was determined by measuring incorporation of 32P-CTP 
in an in vitro assay that has been described previously17.
Selection, purification and adaptation of MADTP-314 resistant virus isolates. To isolate 
MADTP-314-resistant virus variants, a 5-step protocol was used as previously published12. In a first step, Vero 
A cells were seeded in 100 μl of assay medium in 96-well microtiter plates at a density of 2.5 × 104 cells/well and 
were allowed to adhere overnight. Subsequently, antiviral assays with MADTP-314 were set up using dilutions 
with different CCID50 of CHIKV 899 (ranging from 10 to 1000 CCID50). After 5 days of incubation, all assay 
wells were checked microscopically and quantitative data on cell survival were collected using the MTS/PMS 
method (see before). Based on these data, the lowest concentration of compound and the highest virus input 
at which complete and reproducible inhibition of virus-induced CPE was observed were selected. In a second 
www.nature.com/scientificreports/
9Scientific RepoRts | 6:31819 | DOI: 10.1038/srep31819
step, three 96-well plates (a total of 144 assay wells) containing adherent Vero A cells were infected with the most 
optimal virus dilution (50 CCID50) and compound concentration (93 μM). After 5 days of incubation, most assay 
wells did not show any signs of virus-induced cell death. However, in some wells, virus break-through could be 
observed and the supernatant of the 3 wells with the most pronounced signs of virus-induced CPE was collected. 
These samples were purified in 6-fold by titration (1:5 dilution series) in the presence of 93 μM of MADTP-314. 
Three virus isolates (one from each original sample) were selected that produced the most pronounced signs of 
CPE in the presence of MADTP-314 at the lowest virus input possible. Subsequently, the resistant phenotype 
of the selected virus isolates was determined in comparison with wild-type virus. In parallel, the genotype was 
determined by full genome sequencing.
Sequencing. Eight overlapping PCR amplicons were generated from viral RNAs previously extracted from 
the wild-type CHIKV 899 strain and from the putative-resistant virus isolates. Amplicons were generated by the 
OneStep RT-PCR kit (Qiagen), were gel purified and sequenced (BigDye® Terminator v3.1 Cycle Sequencing 
Kit ABI) using primers that were published before12. The complete nucleotide sequences were assembled in 
ContigExpress (VNTI, Invitrogen) and the genomes of the resistant isolates were compared to the wild-type 
genome.
Reverse genetics. Mutations were introduced in the infectious cDNA clone19 of CHIKV LS3 using the 
QuickChange mutagenesis kit (Agilent) according to the manufacturer’s instructions. The sequences of the used 
oligonucleotides are available upon request. Constructs were verified by sequencing using the BigDye Terminator 
Cycle Sequencing Kit v1.1 (Applied Biosystems) and a 3130 Genetic Analyzer automatic sequencer (Applied 
Biosystems). CHIKV was produced from these plasmids as described elsewhere19. Briefly, RNA was transcribed 
using the AmpliScribe T7 high yield transcription kit (Epicenter), the m7GpppA RNA cap structure analogue 
(NEB) and 0.7 μg of linearized template DNA. BHK-21 cells were electroporated with in vitro transcribed RNA 
using the Amaxa Nucleofector according to the manufacturer’s instructions. Infectious CHIKV from the super-
natant of transfected cells (P0) harvested the day after transfection was used to grow working stocks (P1) of WT 
and mutant viruses on Vero E6 cells, which were used for further experiments. To confirm the presence of the 
introduced mutations (and absence of other mutations) the complete genomes of mutant viruses were sequenced 
by extracting viral RNA from virus stocks (P1) using the QIAamp Viral RNA Mini Kit (Qiagen). This RNA was 
used to generate four overlapping amplicons by reverse transcriptase PCR amplification which were sequenced 
completely.
VEEV nsP1 enzyme assays. The protocols for VEEV nsP1 enzyme assays were adapted from18. In short, 
the codon optimized DNA encoding nsP1 of VEEV (strain P676, amino acid 1 to 535) was cloned into the 
expression vector pET28b (Novagen). Recombinant protein was produced in E. coli Rosetta pLysS (DE3) cells 
(Novagen), and then purified by IMAC chromatography. Site-directed mutagenesis was performed using the 
Quikchange site-directed mutagenesis Kit (Stratagene). The methyltransferase assay was carried out in a 20-μL 
reaction mixture, containing 50 mM Tris (pH 7.0), 2 mM DTT, 10 mM KCl, 2 mM GIDP, 330 nM S-adenosyl 
[methyl-3H] Methionine (83.1 Ci/mmol, PerkinElmer), 10 μM S-adenosylmethionine, 2 μM VEEV nsP1, 5% 
DMSO, and increasing concentrations of MADTPs. After incubation at 30 °C for 1 h, the reaction samples were 
loaded on DEAE-cellulose filter (PerkinElmer), and the filter was washed twice with 20 mM ammonium formate, 
once with H2O, and once with absolute ethanol. The filter was dried, and the radioactivity was measured by scin-
tillation counting with SCINT BETAPLATE solution in a Wallac MicroBeta Trilux 1450 counter (PerkinElmer). 
The VEEV nsP1 guanylylation reactions were performed in 20 μL buffer containing 50 mM Tris (pH 7.0), 2 mM 
MgCl2, 2 mM DTT, 10 μM m7GTP, 100 μM AdoHcy and 2 μM nsP1 and incubated 1 h at 30 °C. Next, reactions 
were stopped, and subjected to western blot or ELISA using firstly anti-m3G/m7G-cap monoclonal antibody 
(Synaptic Systems) and secondary peroxidase-conjugated rabbit anti-mouse antibody (Sigma, #A9044). For the 
Western blot assay, the immunoreactive proteins were detected using the Pierce ECL Western Blotting Substrate 
(ThermoScientific) and a Kodak Image Station 4000MM Pro (Carestream Health, Inc.). The signal was quantified 
using ImageJ software.
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